Astrocytoma, Atypical Teratoid/Rhabdoid Tumor, Clear Cell Sarcoma, Ependymoma, Ewing's Sarcoma, Germ Cell Tumor, Glioma, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, Renal Cell Carcinoma, Retinoblastoma, Rhabdoid Tumor, Rhabdomyosarcoma, Wilms Tumor
Conditions
Keywords
pediatrics, sirolimus, relapse
Brief summary
The best treatment for recurrent cancers or those that do not respond to therapies is not known. Typically, patients with these cancers receive a combination of cancer drugs (chemotherapy), surgery, or radiation therapy. These treatments can prolong their life but may not offer a long-term cure. This study proposes using a drug called Sirolimus in combination with common chemotherapy drugs to treat patients with recurrent and refractory solid tumors. Sirolimus has been found to inhibit cell growth and to have anti-tumor activity in pediatric solid tumors in previous studies and, therefore, has the potential to increase the effectiveness of the chemotherapy drugs when given together. This study wil investigate the highest dose of Sirolimus that can be given orally with other oral chemotherapy drugs. Cohorts of 2 subjects will be started at the minimum dose. The dose will be increased in the next 2 subjects as long as there were no major reactions in the previous groups. This study will also seek to learn more about the side effects of sirolimus when used in this combination and what effects the drug has on the white cells and the immune system. Successful use of this drug will impact the cancer population greatly by providing an increased chance of survival to those with resistant or recurrent cancers.
Detailed description
Sirolimus, is a potent immunosuppressive drug that is approved for use in prevention against allograft rejection following solid organ transplant. It has anti-tumor effects mainly by blocking signals which drive cells from G1 to S phase during cell cycle through inhibition of mTOR, thus inhibiting cell growth. Sirolimus, as well as other mTOR inhibitors, has shown anti-tumor activity in pediatric solid tumor xenografts. Children with relapsed and/or refractory solid tumors are in need of novel therapeutic approaches. One option for these patients is the use of prolonged exposure to low dose antiangiogenic chemotherapy, with agents such as etoposide and cyclophosphamide. In this phase I trial the feasibility and optimal dosing for daily sirolimus, in combination with daily celecoxib, and low dose etoposide alternating with cyclophosphamide, will be determined in children with relapsed and refractory solid tumors. p70S6 kinase inhibition will be used as a surrogate for mTOR inhibition. The potential immunosuppressive effect of sirolimus administered on this schedule will be assessed by serial lymphocyte subsets and assessment of memory T cell number.
Interventions
DRUGsirolimus
daily administration of sirolimus in oral form starting at a dose of 1 mg/m2 and increasing to a possible 3 mg/m2.
Sponsors
Children's Healthcare of Atlanta
Emory University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 30 Years
Healthy volunteers
No
Inclusion criteria
* must be \<=30 years of age at time of study enrollment * histologic verification of malignancy at original diagnosis or relapsis except in patients with intrinsic brain stem tumors, optic pathway gliomas or patients wtih pineal tumors and evaluations of serum or CSF alpha-fetoprotein or beta-HCG * measurable or evaluable disease * disease state must be one for which there is no known curative therapy * Performance level \>=50% * Patients must have fully recovered from acute toxic effects of all prior chemotherapy, immunotherapy or radiotherapy * no evidence of acute graft vs. host disease and \>=3 months since transplant * organ function as defined in eligibility section of protocol
Exclusion criteria
* patients cannot be pregnant or breast-feeding * patients must agree to use of an effective contraceptive method * no growth factors that support platelet or white cell number or function for at least 7 days prior to enrollment * patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the prior 7 days are not eligible * patients receiving any other investigational drugs * patients receiving any other anti-cancer drugs * patients who have an uncontrolled infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose (MTD) | 2 years after treatment starts | estimate the maximum tolerated dose (MTD) and recommended Phase II dose of sirolimus administered orally once daily for 42 days in combination with metronomic chemotherapy in children with recurrent or refractory solid tumors. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| define and describe toxicities of sirolimus | 2 years post treatment | To define and describe the toxicities of sirolimus administered in combination with metronomic chemotherapy administered according to this schedule. |
| anti-tumor activity of sirolimus | 2 years post treatment | To assess the antitumor activity of sirolimus administered in combination with metronomic chemotherapy to children with recurrent and refractory solid tumors within the confines of a Phase I study. |
| evaluate correlation of p70S6 kinase activity | 2 years post treatment | To evaluate the correlation of p70S6 kinase activity inhibition with tumor response. |
| evaluate risk of infection | 2 years post treatment | To evaluate the effect of this combination therapy on lymphocyte subsets and memory T-cells, and to correlate that with risk of infection. |
Countries
United States
Outcome results
None listed